Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD19 CAR NK cells in R/R DLBCL
NCT05673447Phase 1Unknown
- Sponsor
- Changhai Hospital
- Start
- Mar 2023
- Primary completion
- Dec 2023
- Modality
- CAR-T Cells, Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD19 CAR NK cells in diffuse large B-cell lymphoma (DLBCL), sponsored by Changhai Hospital. Primary endpoints: Incidence of dose limiting toxicity at 4 weeks and Incidence of Treatment Emergent Adverse Events at 48 weeks. Status: unknown.
02
Drugs
CD19 CAR NK cells
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05673447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05673447.